

# Oncology Research and Treatment

Offizielles Organ von

DGHO – Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie

OeGHO – Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie

DFaG – Deutsche Fatigue Gesellschaft

AIO – Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V.

SGH-SSH – Schweizerische Gesellschaft für Hämatologie

Mitglied der Deutschen Krebsgesellschaft e.V.

## Editors

### *Editor-in-Chief*

M. Hallek, Köln

### *Associate Editors*

S. Al-Batran, Frankfurt/M.

C. Berking, München

C. Bokemeyer, Hamburg

M. Borner, Bern

T. Cerny, St. Gallen

H. T. Eich, Münster

A. Engert, Köln

M. Fassnacht, Würzburg

B. Groner, Frankfurt/M.

V. Heinemann, München

M. Hentrich, München

R. D. Issels, München

W. Janni, Ulm

U. R. Kleeberg, Hamburg

H. Lang, Mainz

M. Moehler, Mainz

M. Schuler, Essen

R. Stupp, Zürich

M. Theobald, Mainz

R. Thomas, Köln

U. Wedding, Jena

J. A. Werner, Marburg

O. Zivanovic, New York

## Editorial Board

P. Albers, Düsseldorf

C. Bausewein, München

L. Bergmann, Frankfurt/M.

J. Boos, Münster

P. Brossart, Bonn

W. Budach, Düsseldorf

R. Büttner, Bonn

J. Debus, Heidelberg

E. Dippel, Ludwigshafen

A. Du Bois, Essen

T. Fehm, Düsseldorf

F. Geiser, Bonn

N. Harbeck, München

A. Heidenreich, Aachen

U. Herrlinger, Bonn

A. Hochhaus, Jena

R.-D. Hofheinz, Mannheim

F. Honecker, St. Gallen

V. Jacobs, Salzburg

K. Jordan, Halle

U. Keilholz, Berlin

J. P. Klussmann, Gießen

H. Kölbl, Wien

W. Kuhn, Bonn

H.-J. Lenz, Los Angeles

P. Mallmann, Köln

H. Moch, Zürich

K. Possinger, Berlin

P. Reichardt, Bad Saarow

S. Reske, Ulm

I. Runnebaum, Jena

P. Schöffski, Leuven

C. Spitzweg, München

I. Strohscheer, St. Peter-Ording

S. Ugurel, Graz

R. Voltz, Köln

M. Weller, Zürich

## Editorial Office

S. Karger GmbH

Attn. Dr. Steffi Hentzelt

P.O. Box

D-79095 Freiburg

E-mail s.hentzelt@karger.com

**KARGER**

Basel · Freiburg · Paris · London · New York · Chennai · New Delhi ·  
Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney

**Editorial**

---

- 376 Primary Central Nervous System Lymphoma in the Elderly**  
Weller, M. (Zurich)

**Original Articles**

---

- 378 Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen**  
Lee, S.; Okoshi, Y.; Kurita, N.; Seki, M.; Yokoyama, Y.; Maie, K.; Hasegawa, Y.; Chiba, S. (Tsukuba)
- 384 Distress in Cancer Patients and Their Caregivers and Association with the Caregivers' Perception of Dyadic Communication**  
Haun, M. (Heidelberg/Berne); Sklenarova, H.; Brechtel, A.; Herzog, W.; Hartmann, M. (Heidelberg)
- 390 Complementary and Alternative Medicine in German Cancer Centers**  
Henf, A.; Wesselmann, S.; Huthmann, D. (Berlin); Muenstedt, K. (Giessen); Huebner, J. (Frankfurt/M./Berlin)
- 396 Thymic Epithelial Tumors: Analysis of Prognostic Factors with Emphasis on the Role of Adjuvant Radiation Therapy**  
Yirmibeşoğlu Erkal, E.; Akgül, A.G.; Halis, H.; Liman, T.; Sarper, B.; Topçu, S.; Aksu, G. (Kocaeli)
- 400 Staging of Primary Breast Cancer Is not Indicated in Asymptomatic Patients with Early Tumor Stages**  
Debald, M.; Wolfgarten, M.; Kreklau, P.; Abramian, A.; Kaiser, C.; Höller, T.; Leutner, C.; Keyver-Paik, M.-D. (Bonn); Braun, M. (Munich); Kuhn, W. (Bonn)
- 406 Meta-Analyses of the Effect of *CYP1A1* and *CYP2D6* Polymorphisms on the Risk of Head and Neck Squamous Cell Carcinoma**  
Han, J.; Wang, L.; Yang, Y.; Zhang, J. (Yan'an)

**Novel Insights from Clinical Practice**

---

- 412 CyberKnife Treatment for Kaposiform Hemangioendothelioma of the Ilium in an Adult: Case Report and Review of Literature**  
Wang, Z.; Kong, Q.-T.; Wu, X.-H.; Li, B.; Shen, Z.-T.; Li, J.; Zhu, X.-X. (Nanjing)

**Review Article**

---

- 418 DNA Repair Gene – *XRCC1* in Relation to Genome Instability and Role in Colorectal Carcinogenesis**  
Nissar, S.; Sameer, A.S.; Rasool, R.; Rashid, F. (Srinagar)

- 424** Reports of Oncological Societies  
**426** PharmaForum  
**430** PharmaNews / Pharma Ticker  
**438** Meetings and Conferences  
**440** Guidelines for Authors  
**416** Imprint

## Imprint

**ISSN Print Edition:** 2296-5270

**ISSN Online Edition:** 2296-5262

**Journal Homepage:** <http://www.karger.com/ort>

**Publication Data:** Volume 37, 2014 of 'ONCOLOGY RESEARCH AND TREATMENT' appears with 12 issues.

**Copyright:** © 2014 by S. Karger Verlag für Medizin und Naturwissenschaften GmbH, Freiburg (Germany). All rights reserved. No part of the journal may be reproduced in any form without the written permission of the publisher. This includes digitalisation and any further electronic computing, like saving, copying, printing or electronic transmission of digitalized material from this journal (online or offline). Authorization to photocopy items for internal or personal use of specific clients is granted by Karger.

**Photocopying:** This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger GmbH, Wilhelmstraße 20A, 79098 Freiburg (Germany).

**Disclaimer:** The statements and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

**Distribution and Subscription:** Karger offers three types of subscription: Print Only, Online Only and the combined Print + Online. The basic annual subscription rate is the same for all three delivery forms; however, a fee for the combined print and online subscription is levied, and there is a postage and handling charge for Print Only and Print + Online. Subscriptions run for a full calendar year. Prices are given per volume.

Print subscription: EUR 261.– + postage and handling.

Online subscription: EUR 261.–.

Combined (print + online) subscription: 311.– + postage and handling.

For customers in Germany: Please turn to your bookshop or to

S. Karger Verlag für Medizin und Naturwissenschaften GmbH

Wilhelmstr. 20A, 79098 Freiburg (Germany)

Tel. +49 761 45 20 70, Fax +49 761 45 20 714

E-mail [information@karger.com](mailto:information@karger.com)

For customers in all other countries: Please contact your bookshop or

S. Karger AG

Allschwilerstr. 10, 4009 Basel (Switzerland)

Tel. +41 61 3 06 11 11, Fax +41 61 3 06 12 34

E-mail [karger@karger.com](mailto:karger@karger.com)

**Advertising:** Correspondence should be addressed to the publisher.

S. Karger Verlag für Medizin und Naturwissenschaften GmbH

Attn. Ellen Zimmermann (Head of Marketing)

E-mail [e.zimmermann@karger.com](mailto:e.zimmermann@karger.com)

Price list No. 24 of January 1, 2014 is effective.

**V.i.S.d.P.** (Person responsible according to the German Press Law):

Sibylle Gross

**Type setting and printing:** Bosch-Druck GmbH, 84030 Ergolding, Germany.

### Bibliographic Services

Biological Abstracts  
Current Contents/Clinical Medicine  
Excerpta Medica/EMBASE  
Index Medicus/MEDLINE  
Medical Documentation Service  
Reference Update  
Research Alert  
Science Citation Index  
SCISEARCH Database

**KARGER**

© 2014 S. Karger GmbH, Freiburg

Fax +49 761 4 52 07 14  
Information@Karger.com  
[www.karger.com](http://www.karger.com)

Accessible online at:  
[www.karger.com/ort](http://www.karger.com/ort)

### Submission

ONCOLOGY RESEARCH AND TREATMENT is a peer-reviewed journal intended to provide a forum for presentation of all aspects of oncology, including reviews and original articles from hematology and medical oncology, surgical, gynecological and urological oncology, radiation therapy as well as clinical-experimental oncology. Contributions to pediatric, ENT and dermatological oncology, pathology, biometry, epidemiology, prevention, early diagnosis and psychological care will also be considered. Manuscripts must be submitted online: [www.karger.com/ort](http://www.karger.com/ort)

Should you have any problems with electronic submission please contact the Editorial Office:

S. Karger Verlag für Medizin und Naturwissenschaften GmbH  
Attn.: Dr. Steffi Hentzelt  
P.O. Box  
79095 Freiburg (Germany)  
Tel. +49 761 45 20 725  
Fax +49 761 45 20 714  
[s.hentzelt@karger.com](mailto:s.hentzelt@karger.com)

### Language

All contributions must be written in English (American or British spelling and grammar).

### Types of Papers and Allotted Number of Pages

Please print the manuscript 1 1/2-spaced with 3-cm margins (left and right). Use only one format (normal) for the document.

The text (including the summary) should be limited to the following number of pages:

	Printed pages	Equals approx. characters*
Review Article, Original Article	5	30,000
Novel Insights from Clinical Practice (formerly Case Report)	3	18,000
Ongoing Clinical Trial, Oncological Education, Clinical Information	4	24,000
Letter to the Editor	1	6,000
Others	2	12,000

\*including title page, summary, illustrations, tables, and references. Tables and figures count for 1,500 characters each. Each additional complete or partial page to print will be charged to the author.

**Novel Insights from Clinical Practice (formerly Case Report):** The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. Highlighted boxes containing one or two bullet points on 'Established facts' (what is already known) and 'Novel insights' (what new information has been gained) are required and should be placed on the first page of the report. These should highlight the novelty of the clinical observation. The manuscript should be presented with an abstract (max. 200 words), followed by introduction, case report and discussion.

### Conditions

Acceptance of a manuscript is based on the evaluation by several reviewers (peer review).

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance.

Once the manuscript is accepted for publication, all usage rights will be retained by the publisher. The assignment of usage rights applies to all print media as well as electronic offline and online media, including the Internet and data bases/data carriers of any kind. Accepted papers, in whole or in part, may not be translated into other languages, or reproduced by any mechanical or electronic means (including photocopying, recording and microcopying), or stored in a retrieval system without the written consent of the publisher.

It is the authors' responsibility to obtain permission to produce illustrations, tables, etc. from other publications.

The publisher reserves the right to edit the manuscript and decide on the layout.

### Disclosure Statement

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

### Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925-926]. Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.

### Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

### Arrangement

**Title page:** The first page of each paper should indicate the title and a short title for use as running head.

**Authors' affiliations and address of correspondence:** Each author's full name, followed by their affiliation (hospital, institute etc. where the work was conducted) and the exact postal address of the corresponding author complete with postal code must be given. Please also supply phone and fax numbers, as well as e-mail address.

**Key Words:** For indexing purposes, a list of 3-5 key words is essential. Whenever possible, use key words such as found in the Medical Subject Headings List (MeSH) of Index Medicus.

**Summary:** The summary must not exceed 200 words. Summaries of Original Articles and Case Reports should be structured as follows: Background (or Introduction), Patients and Methods (or Material and Methods), Results, Conclusion.

**Footnotes:** Footnotes should be used only for tables.

**Registered Trade Names:** When first mentioned, registered trade names must be marked with the superscript registration symbol ® or ™. It is the sole responsibility of the author to ensure that this rule is followed properly.

**Tables and Illustrations:** Tables and illustrations should be prepared on separate pages. Tables require a heading and figures a legend. The number of figures and tables should be limited and aim to illustrate the text. Figures are listed in the text as (fig. 1), tables as (table 1). Data already mentioned in the text need not be repeated in a table. Accordingly, numbers used in tables need not be repeated in the text.

Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 600 dpi.

**Color illustrations** are reproduced at the author's expense. Each one is charged to the author at EUR 300,- + VAT as contribution to the additional reproduction and color printing costs.

### References

The list of references should include only the publications cited in the text. The list should not exceed 60 references for reviews.

References must be numbered sequentially in the order cited in the text. In the text identify references by Arabic numerals [in square brackets]. Preferably please cite all authors.

It is recommended to quote only articles already published or accepted for publication. Please avoid 'in preparation' or 'personal communication'.

Authors are responsible for the accuracy and completeness of their references and for correct citation.

Journal titles should be abbreviated according to the Index Medicus system ([www.nlm.nih.gov](http://www.nlm.nih.gov)). If a reference manager is used, the style 'Pharmacology' or 'Nephron' should be chosen.

Examples for references can be found at [www.karger.com/ort\\_gl](http://www.karger.com/ort_gl).

**Reference Management Software:** Use of EndNote is recommended for easy management and formatting of citations and reference lists.

### Page Charges

There are no page charges for papers that do not exceed the allotted size (cf. types of papers). Each additional complete or partial page is charged to the author at 400,- EUR + VAT.

### Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author. No page proofs are supplied.

### Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.